Forward P/S Multiple: Orchestra BioMed, Inc. (OBIO)
The projected P/S trend reflects market expectations, where 12.20 represents the latest metric reading for Orchestra BioMed (OBIO). The production of cardiac systems remains stable following the implementation of laser automation. Physicians value the brand for its safe methods of targeted drug delivery into blood vessels. Revenues are based on B2B contracts with industry leaders in the treatment of cardiac pathologies.
Summary analytical data breakdowns for orchestrabiomed.com (OBIO)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Orchestra BioMed|OBIO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Orchestra BioMed, Inc.|OBIO - Company Aggregate Debts|Debt to Book Capitalization Ratio Orchestra BioMed, Inc.|OBIO - Company Long-Term Debt|Company Current Liabilities Orchestra BioMed|Quick Ratio orchestrabiomed.com
- financial results and valuation multiples details:
OBIO - Company Net Income|Expected Profit Orchestra BioMed|OBIO - Market Cap to Net Income Ratio|Projected Price to Earnings Orchestra BioMed|OBIO - PEG Multiple|EV/EBITDA Multiple Orchestra BioMed, Inc.|OBIO - Operating income before deduction of amortization|Earnings per share for the last twelve months Orchestra BioMed|OBIO - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months orchestrabiomed.com|OBIO - Net earnings per share growth this year|Earnings growth forecast for next year Orchestra BioMed
- sales and revenue indicators:
Fundamental company analysis:OBIO (Orchestra BioMed)
Forward P/S assesses the market value of a business relative to expected revenue, allowing an investor to determine the extent of the premium paid for future growth rates. The current projected P/S value of 12.20 reflects market expectations for Orchestra BioMed (OBIO), where the efficiency of implementing sustainable production standards for cardiac devices directly impacts the company's future margins and investment attractiveness.
Who Orchestra BioMed competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|SI-BONE Inc (SIBN) - Projected Price to Revenue|Orthofix International - Forward Price-to-Revenue Multiple|Forward P/S Multiple Bioventus Global BVS|OrthoPediatrics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio treace.com TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed, Inc.)|Price-to-Projected Revenue Ratio RxSight Corp|Forward Price-to-Revenue Multiple ClearPoint (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences SGHT|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical International - Price to Expected Revenue Ratio|vivani.com (VANI) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Xtant Medical (XTNT)|Price-to-Projected Revenue Ratio NeuroOne Medical Technologies Corporation|MODD: Forward Price to Sales|Forward P/S Multiple MYO|Forward Price-to-Revenue Multiple Envoy Medical Inc COCH|Forward P/S Multiple VVOS (Vivos Therapeutics)|Forward Price to Sales NVNO|SINTX Technologies - Forward P/S Multiple|Market Cap to Future Revenue Ratio Tenon Medical Inc.|ReWalk Robotics Ltd (LFWD) - Price-to-Projected Revenue Ratio|AMIX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple IVF|BBLG (bonebiologics.com) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Axonics (AXNX)|BIOL (BIOLASE Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (Dynatronics)|Forward P/S Multiple Paragon 28 Inc. FNA|INVO: Forward Price-to-Revenue Multiple
